Makarainen 1986.

Methods	Randomisation by manufacturer using tables for random numbers Double‐blind, placebo‐controlled using cross‐over design No loss to follow‐up No power calculation made
Participants	Finland 13 women, mean age 39 years with a complaint of menorrhagia (subgroup from a total number of 30 women: primary menorrhagia (n = 13), myoma‐associated menorrhagia (n = 10), factor VIII deficiency (n = 1) and normal blood loss (n = 6)) No exclusions specifically mentioned
Interventions	Group 1: ibuprofen 600 mg daily throughout menstrual cycle (maximum 10 days), n = 13 Group 2: ibuprofen 1200 mg daily throughout menstrual cycle (maximum 10 days), n = 13 Group 3: placebo same dosage regimen, n = 13
Outcomes	MBL (alkaline haematin method) Adverse events (any vs none) Duration of bleeding (days) Menstrual pain
Notes	No ITT analysis Data not available at end of first treatment period and so not suitable for pooling Data not given by author for duration of bleeding or menstrual pain
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Tables of random numbers
Allocation concealment (selection bias)	Unclear risk	Unclear risk
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported
Other bias	Unclear risk	Nothing detected